BioSpace News Archive

The US Patent Office (USPTO) has granted HepaTx patent number 11291691 covering the company’s technology to manufacture hepatocyte-like cells to treat liver disease.

Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to support Cumberland’s new Sancuso® oncology support product.

Therapeutic Solutions International, Inc. announced today filing of an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) seeking permission to treat 10 patients with advanced COPD using its universal donor adult stem cell product termed “JadiCell™”.

CYduct Diagnostics, Inc. is pleased to announce it has joined BioCT, Connecticut’s Biosciences Community.

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of diagnostics for neurological disorders and conditions, including Alzheimer’s disease (AD), announces it will present “Physicians’ Assessment of the Clinical Utility of a Novel Test to Diagnose Alzheimer’s Disease (AD),” at the Professional Society for Health Economics and Outcomes Research (ISPOR) Annual Conference.

The Analgesic Program, which commenced in July 2018 to discover and develop peptide-based therapeutics for moderate to severe pain and inflammation, and was successfully completed in March 2021.

At the ISMRM 2022 conference, Bruker announced the launch of innovative 7 Tesla and 9.4 Tesla conduction-cooled Maxwell magnets for its market-leading preclinical magnetic resonance imaging systems portfolio.

BIOQUAL, Inc., Announces Creation of the Role of Chief Scientific Officer and Appointment of Hanne Andersen Elyard, PhD, As the Initial Chief Scientific Officer.

BIOQUAL, Inc., announced that Dave Newcomer will retire from his role as Chief Financial Officer effective June 3, 2022.

Novavax, Inc. (NASDAQ: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced its financial results and operational highlights for the first quarter ended March 31, 2022.